Log in | Jump |
Biomedical investment and business development chatter





Archives

This post was commissioned on April 17, 2008, and it was categorized as FDA/Regulatory.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

I’ve been having migraines lately, well for the last few years. Terrible migraines. Migraines so debilitating only a combination of acutely acting medicines could even touch the pain. The problem was, up until now (finally, after a two year delay), I had to open two bottles of medicine, remove a few pills and either swallow the lot of them at once - or sometimes - in two separate gulps! Can you imagine the suffering? Can you imagine how many seconds I’ve wasted in the last few years going through this procedure every time I have a blinding headache?

Well, thanks the souls at GSK for running the trial and bringing help to those who really really need it. Treximet was finally approved by the FDA this week and I don’t have to open two bottles anymore. I can now get both naproxen (~$6/mo) and Imitrex (sumatriptan - $200/mo) in one easy to swallow (and time saving) pill. Some speculate that Treximet was a pure life-cycle management play from GSK due to the looming patent expiration the blockbuster sumatriptan in 2009. I say differently. GSK and POZEN are interested in saving patients like me time and money (well, maybe not money).

I haven’t decided what I’ll do with all the extra time I’ll save… maybe read War and Peace, volunteer at a local animal shelter or learn Italian. God bless Treximet.

(Photo by miss_rogue on Flickr. Work licensed under a Creative Commons copyright.)

Theoretically Related Posts

This post was constructed by .

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
_blank _blank _blank _blank _blank _blank _blank

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Viewing 1 Comment

 

Trackbacks

(Trackback URL)

close Reblog this comment
blog comments powered by Disqus